George S. Vassiliou

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Hematological Malignancy, Acquired Mutation, Receptor Tyrosine Kinase +9

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.2K citations · Full text

Hematological Malignancy, Tumor Biology, Medicine +9

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 1.1K citations

Hematological Malignancy, Acquired Mutation, Receptor Tyrosine Kinase +9

Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control

Isaia Barbieri, Konstantinos Tzelepis, Luca Pandolfini et al. · Nature · 2017 · 1.1K citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Promoter-bound Mettl3 +5

Prediction of acute myeloid leukaemia risk in healthy individuals

Sagi Abelson, Grace Collord, Stanley Ng et al. · Nature · 2018 · 844 citations · Full text

Hematological Malignancy, Healthy Individuals, Mixed-phenotype Acute Leukemia +4